ARTL News

Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on Pain

Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain

Form 8-K

Cancer Anorexia Market Insight, Epidemiology, and Market Forecast - 2036 Report Reveals Why a ~$500M Market Still Has No Approved Therapy in the US or Europe as Artelo's ART27.13 Nears Phase II Readout

Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform

Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings

Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity

Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Form 8-K

Artelo Biosciences Announces Reverse Stock Split